^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DDR inhibitor

    Related drugs:
    Apply
    Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (NCT04266912)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    03/17/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    Bavencio (avelumab) • berzosertib (M6620)
    Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) (NCT04711824)
    Phase 1/2
    Colette Shen
    Recruiting
    Last update posted :
    11/22/2024
    Initiation :
    03/09/2022
    Primary completion :
    11/01/2025
    Completion :
    11/01/2026
    HER-2 • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
    Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) (NCT03851614)
    Phase 2
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    04/08/2019
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    HRD • CD4
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months (REVOCAN) (NCT04826198)
    Phase 1/2
    Gustave Roussy, Cancer Campus, Grand Paris
    Recruiting
    Last update posted :
    04/05/2023
    Initiation :
    10/05/2020
    Primary completion :
    10/01/2023
    Completion :
    10/01/2023
    BRCA • MUC16
    |
    Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib) • AsiDNA (etidaligide)
    Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors (NCT05700669)
    Phase 1b/2
    Onxeo
    Recruiting
    Last update posted :
    03/31/2023
    Initiation :
    02/20/2023
    Primary completion :
    12/01/2026
    Completion :
    04/01/2027
    HER-2 • PGR
    |
    HER-2 positive • HR positive • PGR positive
    |
    Lynparza (olaparib) • AsiDNA (etidaligide)